Sino Biopharmaceutical’s invoX Pharma subsidiary does not anticipate a favorable outcome from the Committee on Foreign Investment of the United States, or CFIUS, review of its proposed deal to buy F-Star Therapeutics by the deadline of January 31, said Dealreporter, citing two sources, contacts tell The Fly.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FSTX:
- F-Star Therapeutics Plunges as Sale Falters
- invoX Pharma and F-star Therapeutics issue Joint Statement
- F-star Therapeutics says invoX offer extended to January 17
- F-star says invoX extended offer, in further extension talks after CFIUS warning
- F-star Therapeutics presents clinical data on antitumor activity of FS222